Roflumilast, another PDE4 inhibitor approved for chronic obstructive pulmonary disease (COPD), has similar molecular properties with higher binding affinity to PDE4 and longer plasma halftime [8]. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.